1 TOPBP1 and its fission yeast homologue Rad4, are critical players in a range of DNA 2 replication, repair and damage signalling processes. They are composed of multiple BRCT 3 domains, some of which have the capacity to bind phosphorylated motifs in other proteins. 4
Introduction
1 TOPBP1 and its fission and budding yeast orthologues Rad4 and Dpb11, respectively, are 2 scaffold proteins that mediate formation of multi-protein complexes in a range of essential 3 DNA replication and repair processes (Wardlaw et al., 2014) . Homologues in vertebrates 4 each contain nine BRCT domains, of which four (at the N-terminus; BRCT1,2 and 4,5) are 5 genetic and biochemical studies show that they are nonetheless selective and specific for the 16 phosphopeptide sequences with which they interact. However, the structural basis for this 17 specificity has not been defined. 18
To gain some insight into this, we have determined crystal structures of segments of yeast 19 and vertebrate TOPBP1 that contain the two most N-terminal phosphopeptide binding sites 20 (BRCT1 and BRCT2), in complex with phosphopeptides derived from a number of different 21 known ligand proteins, including RAD9, and used this to develop consensus patterns that 22 encapsulate the individual specificity requirements of these two independent binding sites. 23
We have used these patterns to predict interacting phospho-peptides from putative ligand 24 residue maintains a consistent b-sheet conformation, and does not contain the tight turn seen 1 for the hydrophobic triplets in peptides bound to the BRCT1 domain of TOPBP1 or Rad4. 2 3
Structural basis for peptide selectivity by BRCT1 and BRCT2 4
Comparison of the BRCT1 and BRCT2 domains of TOPBP1 and of Rad4 suggests 5 conserved features that govern the different conformation of their ligand peptides and 6 contribute to selectivity. A common feature of all TOPBP1/Rad4 BRCT1 or BRCT2 ligands 7 so far identified, is the presence of a hydrophobic residue at -3 relative to the phosphorylated 8 serine or threonine. In both BRCT1 and BRCT2 this residue packs into a hydrophobic recess 9
formed by side chains projecting from the a-helix connecting the 3 rd and 4 th b-strand of the 10 BRCT fold. In BRCT1 this recess is extended and is sufficiently large to accommodate two 11 consecutive hydrophobic side chains of a peptide ligand so long as the backbone of the 12 peptide adopts a tight turn conformation (FIGURE 3A,B) . In BRCT2 however, the size of the 13 recess is restricted by the side chain of a highly conserved tryptophan residue (Trp158 in 14
Rad4; Trp257 in human TOPBP1) at the C-terminal end of the a-helix, and can only 15 accommodate a single hydrophobic side chain, requiring that the peptide chain continues in 16 an extended b-sheet conformation (FIGURE 3C,D). 17
Based on the available crystal structures, the major factor that determines binding to BRCT1 18 seems to be the ability of the peptide sequence upstream of the phosphorylated residue to 19 form a tight turn that places the side-chains of the -3 and -4 residues into the extended 20 hydrophobic recess. Sequences with hydrophobic residues at -3 and -4 (and often -5) as in 21 the RAD9-pS387, Crb2-pT187, Sld3-pT636 and Treslin-pS1001 (993-DIGVVEEpSP) 22
peptides conform to this requirement, whereas sequences with large polar side chains such 23 as Crb2-pT235 where -4 is arginine, or Sld3-pT650 where -4 is glutamate, do not, and are 24 restricted to binding to BRCT2. A subtler effect is seen with the Treslin-pT969 site (962-1 LTKSVAEpTP), which has a small polar amino acid -serine -at -4, and binds preferentially 2 to BRCT2 (FIGURE 3E) when presented in the context of a short peptide. However, the 3 unfavourability of the small polar serine, which unlike arginine or glutamate could at least be 4 sterically accommodated by BRCT1, is diminished in the context of a longer peptide (Boos 5 et al., 2011) . Binding to BRCT2 appears to be less selective beyond the requirement for a 6 hydrophobic residue at -3. Thus, the Crb2-pT187 sequence is able to bind to Rad4-BRCT2 7
as well as Rad4-BRCT1 with comparable affinity, as can the Treslin-pS1001 sequence to 8 TOPBP1-BRCT1 and TOPBP1-BRCT2. However, the ability to bind to BRCT1 does not 9 guarantee binding to BRCT2, which may depend on the identity of the hydrophobic -3 10 residue. The RAD9-pS387 sequence for example, binds with low micromolar affinity to 11 TOPBP1-BRCT1 where its -3 alanine and -4 leucine can effectively occupy the extended 12 hydrophobic recess, but binds much less tightly to BRCT2 where only the minimal 13 hydrophobic side-chain of the -3 alanine is available to bind. 14
15
Many (but by no means all) of the sites shown to bind to TOPBP1-BRCT0,1,2 or Rad4-16 BRCT1,2 have a proline residue (at +1) following the phosphorylated serine or threonine, 17 and are known (or presumed to be) targets for phosphorylation by CDKs or other proline-18 directed protein kinases (Boos et al., 2011; Qu et al., 2013) . In the observed binding modes 19
for both BRCT1 and BRCT2, the +1 residue is directed away from the body of the protein, 20
and makes no direct contribution to the binding specificity, but is nonetheless accommodated. 21
22

Identification of the TOPBP1-BRCT1,2 binding site in RHNO1 23
Based on the crystal structures described above, and the model for specificity derived from 1 them, we set out to identify hitherto unrecognised interaction motifs in proteins implicated by 2 genetic or proteomic studies in interaction with TOPBP1, but where the basis for that 3 interaction has not been characterised. 4 RHNO1 (aka RHINO, RAD9-Hus1-Rad1 Interacting Nuclear Orphan) was identified as a 5 contributor to DNA damage checkpoint signalling, which physically couples the 9-1-1 (RAD9- other TOPBP1/Rad4-binding sequences, and with a triplet of hydrophobic residues in the -5, 14 -4 and -3 positions that would facilitate high-affinity binding to BRCT1 according to our model. 15
The key attributes of this motif are highly conserved in RHNO1 homologues in metazoa 16
(FIGURE S1). 17
To test the hypothesis that this is a bona fide TOPBP1-binding site, we synthesised a 18 phospho-peptide encapsulating the putative RHNO1-pT202 site and measured its binding to 19 segments of TOPBP1 using fluorescence polarisation. RHNO1-pT202 bound to TOPBP1-20 BRCT0,1,2 with sub-micromolar affinity (FIGURE 4B), but did not show any measurable 21
binding to the other phospho-peptide binding modules of TOPBP1, i.e. BRCT4,5 and 22
BRCT7,8 (FIGURE 4C, D). A dephosphorylated version of the same peptide did not bind. 23
To determine whether RHNO1-pT202 bound BRCT1 or BRCT2 preferentially, we utilised 24 TOPBP1-BRCT0,1,2 mutants that abrogate phospho-peptide binding to BRCT1 (K155E) or 25 to BRCT2 (K250E). We found that the K250E mutant bound the peptide with comparable 1 affinity to the wild-type, whereas no binding was observed with the K155E mutant, confirming 2 TOPBP1-BRCT1 as the major binding site for RHNO1-pT202 (FIGURE 4B). Interestingly, 3 truncation mutations of RHNO1 that eliminate the region of the protein in which this putative 4 phosphorylation site occurs, and which are therefore unlikely to be unable to bind TOPBP1, putative interaction of this region with TOPBP1 is believed to be mediated by the BRCT4, 5 15 module, but is of significantly lower affinity than that displayed by other biologically significant 16
phospho-peptide interactions with TOPBP1/Rad4 BRCT domains (Leung et al., 2013) . To determine whether the single SDT site in Mdb1 mediates an interaction with Rad4, we 21 synthesised a phospho-peptide encapsulating the bis-phosphorylated Mdb1-p216,p218 SDT 22 site and measured its binding to segments of Rad4 using fluorescence polarisation (FIGURE 23 5A). While the Mdb1-p216,p218 peptide bound with sub-micromolar affinity to S.pombe 24 Nbs1, consistent with observations in the human system, no binding was observed to either 1 the BRCT1,2 or BRCT3,4 modules of Rad4. 2
To try and identify other potential phosphorylation sites on Mdb1 that might mediate its 3 interaction with Rad4, we searched the Mdb1 sequence using ScanProsite as before (de kinase consensus and hydrophobic -3 residue seen for many TOPBP1/Rad4 BRCT1 and/or 8 BRCT2 interacting sites. However, based on the presence of a polar residue, threonine at -4 9
our model would suggest that this site would not display high-affinity for BRCT1. 10
To characterise the interaction of this putative site with Rad4, we synthesised a 11 phosphopeptide encapsulating the Mbd1-pT113 site and measured its binding to segments 12
of Rad4 using fluorescence polarisation as above. We found that the Mbd1-pT113 peptide 13 bound to Rad4-BRCT1,2 with low micromolar affinity (FIGURE 5C) but showed no binding to 14
Rad4-BRCT3,4, the equivalent of TOPBP1-BRCT4,5 that has been implicated in mediating 15 MDC1 interactions in the metazoan system (Leung et al., 2013) . To determine which BRCT 16 domains mediate the interaction with Mdb1-pT133, we measured binding to Rad4-BRCT1,2 17 with mutations in BRCT1 (K56E) or BRCT2 (K155E), and found binding was reduced 20-fold 18 compared to wild-type with the BRCT2 mutant but was largely unaffected by mutation of 19
BRCT1 (FIGURE 5C). 20
Based on these observations, we were able to obtain a high-resolution crystal structure of 21
Rad4-BRCT1,2 in complex with the Mdb1-pT113 peptide, confirming the preference for 22
binding to BRCT2 (FIGURE 5D). The structure shows the Mdb1 peptide bound in a very 23 similar conformation as Crb2-pT187, Crb2-pT235 and Sld3-pT650 peptides bound to this 24 domain, with the valine at -3 relative to the phospho-threonine packed into the hydrophobic 25 recess, while the polar threonine at -4 that makes the sequence incompatible with BRCT1, is 1 directed out to solvent by the b-sheet conformation of the peptide backbone. 2
Deletion of Mdb1 only displays significant DNA damage phenotypes in the absence of some 3 other Rad4-interacting proteins, and further work is required to determine whether the 4 phosphorylation site we characterise here plays a critical role in Mdb1 function in vivo. 5
However, analogous TOPBP1-binding sites in mammalian MDC1 appear to play an role in 6 the response to DNA damage in mitotic cells (Ahorner, Jones et al., manuscript submitted). While multiple interacting partners of TOPBP1 are known, the interplay between these has 20 not been studied in depth, and whether multiple ligand proteins participate simultaneously 21 with the same TOPBP1 scaffolded complex is unknown. Our data reveal clear and distinctive 22 specificities for ligand binding between the two phosphopeptide-binding sites in the N-23 terminal BRCT module, and it is likely that this also applies to the conserved central BRCT 24 module, and to the C-terminal BRCT module, which is only present in metazoa. Based on 1 this it is feasible that a single TOPBP1 molecule could, for example, simultaneously bind 9-2 1-1 (via BRCT1) and BLM (via BRCT5), or a single Rad4 molecule bind Crb2 (via BRCT1 3 and 2) and 9-1-1 (via BRCT4). Of course, steric constraints imposed by the rest of the ligand 4 protein outside the phosphopeptide motif, might prevent simultaneous interaction, but 5 multiple combinations are possible at least in principle. 6
Conversely, the mapped BRCT specificities of some ligands potentially rules out their co-7 existence within a TOPBP1/Rad4 scaffolded complex. Thus, both RHNO1 and the RAD9 8 component of the 9-1-1 clamp selectively bind BRCT1 of TOPBP1 and are therefore unlikely 9
to be simultaneously bound to the same TOPBP1 molecule, in contradiction of current models 10 (Lindsey-Boltz et al., 2015). Similarly, Treslin and 9-1-1 in metazoa, or Sld3 and Crb2 in 11 fission yeast, would be in competition for binding to TOPBP1/Rad4. These competitions may 12 be resolved by differences in affinity between binding motifs -for example RHNO1-pT202 13 appears to bind ~10-fold tighter than RAD9-pS387 -and by regulation of the phosphorylation 14 state of individual ligand sites by cell cycle and/or DNA damage response systems. For 15 example, while the RAD9-pS387 site is generated by CK2, which is constitutively active 16 throughout the cell cycle (Pinna, 2002) , the potentially competing RHNO1-pT202 site has the 17 appearance of a CDK site, and its modification and interaction with TOPBP1 might be 18
restricted to a specific cell cycle phase. Although these models for regulation of 19 TOPBP1/Rad4 complex formation are appealing, the situation may be further complicated by 20 the observation that under some circumstances TOPBP1 may be able to oligomerise via 21 interaction of an AKT-dependent phosphorylation site on one TOPBP1 molecule, with the C-22
terminal BRCT7,8 module of another (Liu et al., 2006) . Further work will be required to define 23 the composition of the many different TOPBP1-scaffolded complexes that potentially occur 24 within living cells. 25
Given the many roles of TOPBP1 in maintaining cell viability in the presence of the genomic 1 instability that typically accompanies cancer progression, pharmacological disruption of 2 TOPBP1-BRCT interactions with ligand proteins offers an attractive therapeutic approach. 3
However, the poor cell-permeability of inhibitors targeting the strongly polar phosphate 4
interactions on which binding to BRCT domains often depends, has limited progress (Yuan 5 et al., 2011) . The data presented here show that while phosphate interactions are important, 6 specificity and high-affinity is mediated by a predominantly hydrophobic interaction that 7
should be much more amenable to competitive blockade by cell-penetrant small molecules. 8 9 10
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